(PS) Nasiri v. Pfizer, Inc.

CourtDistrict Court, E.D. California
DecidedOctober 9, 2024
Docket2:24-cv-02111
StatusUnknown

This text of (PS) Nasiri v. Pfizer, Inc. ((PS) Nasiri v. Pfizer, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
(PS) Nasiri v. Pfizer, Inc., (E.D. Cal. 2024).

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 FOR THE EASTERN DISTRICT OF CALIFORNIA 10 11 ZABIULLAH NASIRI, 2:24-cv-02111 KJM CKD (PS) 12 Plaintiff, 13 v. ORDER AND 14 PFIZER, INC., et al., FINDINGS AND RECOMMENDATIONS 15 Defendants. 16 17 Plaintiff’s pro se complaint filed on August 5, 2024, is before the court for screening.1 18 (ECF No. 1.) Plaintiff seeks to proceed in forma pauperis. (ECF No. 2.) Plaintiff’s application 19 makes the showing required by 28 U.S.C. § 1915, and the motion to proceed in forma pauperis is 20 granted. However, the complaint fails to invoke the court’s subject matter jurisdiction and fails to 21 state a claim. Because the complaint’s deficiencies cannot be remedied by amendment, the 22 undersigned recommends the complaint be dismissed without leave to amend. 23 I. Allegations in the Complaint 24 Plaintiff alleges the defendant, Pfizer, Inc., deceived the public with widespread 25 misrepresentation that its vaccine possessed 95% efficacy against COVID-19 infections, among 26 other information that was highly misleading. (ECF No. 1.) Plaintiff alleges harm in the form of 27 1 This matter is before the undersigned for these findings and recommendations pursuant to Local 28 Rule 302(c)(21). See 28 U.S.C. § 636(b)(1). 1 defendant’s conduct impacting “Plaintiff and the public’s decision-making process concerning 2 vaccination status to his/their detriment” based on a distorted risk/benefit analysis caused by 3 defendant’s misrepresentations. (Id. at 55.) “Had plaintiff and the public known the truth about 4 the efficacy of Pfizer’s COVID-19 vaccine, Plaintiff and a substantial portion would likely have 5 opted for an alternative or foregone inoculation altogether.” (Id. at 55-56.) 6 Plaintiff brings this action under “California’s Deceptive Trade Practice Act (‘CDTPA’)” 7 (id. at 6) and the Federal Trade Commission (“FTC”) Act (see id. at 58). In addition, the 8 complaint indicates the claims are brought under California Business and Professional Code § 9 17500, California Business and Professional Code §17500.5, and California Civil Code 1770. (Id. 10 at 1, 6.) 11 The complaint asserts five causes of action as follows: “misrepresentations concerning 12 relative risk reduction;” “misrepresentations concerning durability of protection;” 13 “misrepresentations concerning transmission;” “misrepresentations concerning protection against 14 variants;” and “scheme to conceal vaccine underperformance.” (ECF No. 1 at 58-60.) Plaintiff 15 seeks damages and injunctive relief. (Id. at 61-62.) 16 II. Screening Requirement 17 Pursuant to 28 U.S.C. § 1915(e), the court must screen every in forma pauperis 18 proceeding, and must order dismissal of the case if it is “frivolous or malicious,” “fails to state a 19 claim on which relief may be granted,” or “seeks monetary relief against a defendant who is 20 immune from such relief.” 28 U.S.C. § 1915(e)(2)(B); Lopez v. Smith, 203 F.3d 1122, 1126-27 21 (2000). In reviewing a complaint under this standard, the court accepts as true the factual 22 allegations contained in the complaint, unless they are clearly baseless or fanciful, and construes 23 those allegations in the light most favorable to the plaintiff. See Von Saher v. Norton Simon 24 Museum of Art at Pasadena, 592 F.3d 954, 960 (9th Cir. 2010), cert. denied, 564 U.S. 1037 25 (2011). In addition, the court liberally construes pro se pleadings. See Haines v. Kerner, 404 U.S. 26 519, 520 (1972). A pro se litigant is entitled to notice of the deficiencies in the complaint and an 27 opportunity to amend unless the complaint’s deficiencies could not be cured by amendment. See 28 Noll v. Carlson, 809 F.2d 1446, 1448 (9th Cir. 1987) (explaining that a court should briefly 1 explain a pro se litigant’s pleading deficiencies when dismissing a complaint with leave to 2 amend) (superseded on other grounds by statute as stated in Lopez v. Smith, 203 F.3d 1122 (9th 3 Cir. 2000) (en banc)). 4 III. Discussion 5 At the outset, the court notes plaintiff, as a pro se litigant, can only bring and prosecute 6 claims on behalf of himself, and not the general public. Courts routinely adhere to the general rule 7 prohibiting pro se plaintiffs from pursuing claims on behalf of others in a representative capacity. 8 Simon v. Hartford Life, Inc., 546 F.3d 661, 664 (9th Cir. 2008). 9 In addition, plaintiff cannot state a claim under the Federal Trade Commission Act 10 because there exists no private right of action. See Dreisbach v. Murphy, 658 F.2d 720, 730 (9th 11 Cir. 1981); Kerr v. Am. Home Mortg. Serv’g, Inc., No. 10-cv-1612-BEN-AJB, 2010 WL 12 3743879, at *3 (S.D. Cal. Sep. 22, 2010) (explaining that only the Federal Trade Commission has 13 standing to enforce the Act). While some of the California statutes cited by plaintiff allow 14 individuals to bring a lawsuit, plaintiff fails to invoke the court’s subject matter jurisdiction to sue 15 under those statutes and fails to state a claim under those statutes. 16 The complaint asserts this court has subject matter jurisdiction on the basis of a federal 17 question, “specifically 28 U.S.C. § 2241 U.S.C. § 1983.” (ECF No. 1 at 6.) Section 2241 gives 18 the power to grant a writ of habeas corpus and has no application here. Section 1983 exists to 19 redress violations of rights, privileges, or immunities secured by the Constitution and federal laws 20 by a person or entity acting under the color of state law. See 42 U.S.C. § 1983. Plaintiff does not 21 allege defendant acted under color of state law. Plaintiff also does not plausibly allege a violation 22 of his constitutional or other federal rights. A conclusory assertion that defendant “violated the 23 Eighth and Fourteenth Amendment to the United States Constitution” does not suffice to allege a 24 constitutional violation. See Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007) (“labels and 25 conclusions” do not suffice to state a claim). 26 Accordingly, the complaint fails to invoke the court’s subject matter jurisdiction. 27 Separately, and in addition, plaintiff fails to state a claim under any of the California statutes 28 under which plaintiff brings his claims. 1 California’s Consumer Legal Remedies Act (“CLRA”) makes illegal “unfair methods of 2 competition and unfair or deceptive acts or practices undertaken by any person in a transaction 3 intended to result or which results in the sale or lease of goods or services to any consumer.” Cal. 4 Civ. Code § 1770 (emphasis added). A CLRA claim must satisfy the heightened pleading 5 standard for fraud. See Fed. R. Civ. P. 9(b); Herron v. Best Buy Co. Inc., 924 F.

Related

Jennings v. Mahoney
404 U.S. 25 (Supreme Court, 1971)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Amanda Sateriale v. R J Reynolds Tobacco Company
697 F.3d 777 (Ninth Circuit, 2012)
Von Saher v. Norton Simon Museum of Art at Pasadena
592 F.3d 954 (Ninth Circuit, 2010)
Simon v. Hartford Life, Inc.
546 F.3d 661 (Ninth Circuit, 2008)
Lopez v. Smith
203 F.3d 1122 (Ninth Circuit, 2000)
Laster v. T-Mobile USA, Inc.
252 F. App'x 777 (Ninth Circuit, 2007)
Herron v. Best Buy Co.
924 F. Supp. 2d 1161 (E.D. California, 2013)
Noll v. Carlson
809 F.2d 1446 (Ninth Circuit, 1987)

Cite This Page — Counsel Stack

Bluebook (online)
(PS) Nasiri v. Pfizer, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/ps-nasiri-v-pfizer-inc-caed-2024.